Answers are grounded in this paper and cite their sources.
Examines mechanisms of therapeutic resistance in high-risk lymphoma, suggesting new treatment insights.
In this issue of Blood Cancer Discovery, Yang and colleagues present a comprehensive repository of patient-derived xenograft models of aggressive large B-cell lymphoma. The publicly available resource links disease specimens from individuals treated with diverse modern therapies (including chimeric antigen receptor T cells) to their high-risk clinical treatment histories and the molecular and transcriptional characteristics of their tumors, enabling the study of tumor cell-intrinsic mechanisms of therapeutic resistance and susceptibility to novel therapies. See related article by Yang et al., p. XX .
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: